{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:51:57Z","timestamp":1790812317544,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573509"],"award-info":[{"award-number":["81573509"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Olanzapine is a second-generation anti-psychotic drug used to prevent neuroinflammation in patients with schizophrenia. However, the long-term administration of olanzapine leads to insulin resistance (IR); the mechanisms of this effect remains poorly understood. Using cellular and rodent models of IR induced by olanzapine, we found that chronic olanzapine treatment induces differential inflammatory cytokine reactions in peripheral adipose and the central nervous system. Long-term treatment of olanzapine caused metabolic symptoms, including IR, by markedly elevating the plasma levels of pro-inflammatory cytokines, including IL-1\u00df, IL-6, IL-8 and TNF\u03b1; these findings are consistent with observations from schizophrenia patients chronically treated with olanzapine. Our observations of differential inflammatory cytokine responses in white adipose tissues from the prefrontal cortex in the brain indicated cell type-specific effects of the drug. These cytokines induced IR by activating NF-kB through the suppression of IkB\u03b1. Functional blockade of the components p50\/p65 of NF-kB rescued olanzapine-induced IR in NIH-3T3 L1-derived adipocytes. Our findings demonstrate that olanzapine induces inflammatory cytokine reactions in peripheral tissues without adversely affecting the central nervous system and suggest that chronic olanzapine treatment of schizophrenia patients may cause inflammation-mediated IR with minimal or no adverse effects in the brain.<\/jats:p>","DOI":"10.1038\/s41598-018-36930-y","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T11:05:41Z","timestamp":1549537541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance"],"prefix":"10.1038","volume":"9","author":[{"given":"Huqun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangyu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maosheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiang","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taohua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"key":"36930_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1600-0447.1999.tb05982.x","volume":"395","author":"SE Arnold","year":"1999","unstructured":"Arnold, S. E. Cognition and neuropathology in schizophrenia. Acta Psychiatr. Scand. Suppl. 395, 41\u201350 (1999).","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"36930_CR2","first-page":"249","volume":"37","author":"DB Schnur","year":"1986","unstructured":"Schnur, D. B., Friedman, S., Dorman, M., Redford, H. R. & Kesselman, M. Assessing the family environment of schizophrenic patients with multiple hospital admissions. Hosp. Community Psychiatry 37, 249\u2013252 (1986).","journal-title":"Hosp. Community Psychiatry"},{"key":"36930_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev.med.52.1.503","volume":"52","author":"S Kapur","year":"2001","unstructured":"Kapur, S. & Remington, G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annual review of medicine 52, 503\u2013517, https:\/\/doi.org\/10.1146\/annurev.med.52.1.503 (2001).","journal-title":"Annual review of medicine"},{"key":"36930_CR4","first-page":"2131","volume":"172","author":"AD Stenstrom","year":"2010","unstructured":"Stenstrom, A. D., Christiansen, E., Dehlholm-Lambertsen, B., Nohr-Jensen, P. & Bilenberg, N. Rising incidence rates of schizophrenia among children and adolescents. Ugeskr. Laeger. 172, 2131\u20132135 (2010).","journal-title":"Ugeskr. Laeger."},{"key":"36930_CR5","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00127-013-0726-7","volume":"48","author":"A Castagnini","year":"2013","unstructured":"Castagnini, A. & Foldager, L. Variations in incidence and age of onset of acute and transient psychotic disorders. Soc. Psychiatry Psychiatr. Epidemiol. 48, 1917\u20131922, https:\/\/doi.org\/10.1007\/s00127-013-0726-7 (2013).","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"36930_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1192\/bjp.174.1.31","volume":"174","author":"JH Jenkins","year":"1999","unstructured":"Jenkins, J. H. & Schumacher, J. G. Family burden of schizophrenia and depressive illness. Specifying the effects of ethnicity, gender and social ecology. The British journal of psychiatry: the journal of mental science 174, 31\u201338 (1999).","journal-title":"The British journal of psychiatry: the journal of mental science"},{"key":"36930_CR7","unstructured":"Benjamin, J., Sadock, V. A. S. & Pedro, R. Kaplan and sadock\u2019s comprehensive textbook of psychiatry. (Wolters Kluwer, 2009)."},{"key":"36930_CR8","doi-asserted-by":"publisher","first-page":"e37087","DOI":"10.1371\/journal.pone.0037087","volume":"7","author":"K Fujimaki","year":"2012","unstructured":"Fujimaki, K., Takahashi, T. & Morinobu, S. Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia. PloS one 7, e37087, https:\/\/doi.org\/10.1371\/journal.pone.0037087 (2012).","journal-title":"PloS one"},{"key":"36930_CR9","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S0013-7006(05)82427-3","volume":"31","author":"S Spanarello","year":"2005","unstructured":"Spanarello, S., Beoni, A. M., Mina, G., Amantini, K. & Colotto, A. Analysis of differential clinical profiles of different antipsychotic molecules in the first psychotic episode: a retrospective study. Encephale 31, 692\u2013697 (2005).","journal-title":"Encephale"},{"key":"36930_CR10","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.4088\/JCP.v63n1208","volume":"63","author":"JJ Caro","year":"2002","unstructured":"Caro, J. J., Ward, A., Levinton, C. & Robinson, K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. The Journal of clinical psychiatry 63, 1135\u20131139 (2002).","journal-title":"The Journal of clinical psychiatry"},{"key":"36930_CR11","doi-asserted-by":"publisher","first-page":"967302","DOI":"10.1155\/2012\/967302","volume":"2012","author":"R Jairam","year":"2012","unstructured":"Jairam, R., Prabhuswamy, M. & Dullur, P. Do we really know how to treat a child with bipolar disorder or one with severe mood dysregulation? Is there a magic bullet? Depression research and treatment 2012, 967302 (2012).","journal-title":"Depression research and treatment"},{"key":"36930_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/da.22378","volume":"32","author":"JF Goldberg","year":"2015","unstructured":"Goldberg, J. F. et al. The American society of clinical psychopharmacology survey of psychopharmacologists\u2019 practice patterns for the treatment of mood disorders. Depression and anxiety 32, 605\u2013613 (2015).","journal-title":"Depression and anxiety"},{"key":"36930_CR13","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/pds.1424","volume":"16","author":"MD Drici","year":"2007","unstructured":"Drici, M. D. & Priori, S. Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiol. Drug Saf. 16, 882\u2013890 (2007).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"36930_CR14","first-page":"CD006633","volume":"10","author":"C Asenjo Lobos","year":"2010","unstructured":"Asenjo Lobos, C. et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 10, CD006633 (2010).","journal-title":"Rev."},{"key":"36930_CR15","first-page":"11r01174","volume":"13","author":"MG Nashed","year":"2011","unstructured":"Nashed, M. G., Restivo, M. R. & Taylor, V. H. Olanzapine-induced weight gain in patients with bipolar I disorder: a meta-analysis. Prim. Care Companion CNS Disord. 13, 11r01174 (2011).","journal-title":"Prim. Care Companion CNS Disord."},{"key":"36930_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40263-015-0308-1","volume":"30","author":"RC Harvey","year":"2016","unstructured":"Harvey, R. C., James, A. C. & Shields, G. E. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. CNS drugs 30, 27\u201339 (2016).","journal-title":"CNS drugs"},{"key":"36930_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/eip.12251","volume":"10","author":"C Tek","year":"2016","unstructured":"Tek, C. et al. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early intervention in psychiatry 10, 193\u2013202 (2016).","journal-title":"Early intervention in psychiatry"},{"key":"36930_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0920-9964(02)00498-X","volume":"66","author":"PJ Weiden","year":"2004","unstructured":"Weiden, P. J., Mackell, J. A. & McDonnell, D. D. Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia research 66, 51\u201357 (2004).","journal-title":"Schizophrenia research"},{"key":"36930_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3371\/CSRP.4.1.6","volume":"4","author":"D Velligan","year":"2010","unstructured":"Velligan, D. et al. Methodological challenges in psychiatric treatment adherence research. Clin. Schizophr. Relat. Psychoses 4, 74\u201391 (2010).","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"36930_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2174\/0929867043456043","volume":"11","author":"A Serretti","year":"2004","unstructured":"Serretti, A., De Ronchi, D., Lorenzi, C. & Berardi, D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Current medicinal chemistry 11, 343\u2013358 (2004).","journal-title":"Current medicinal chemistry"},{"key":"36930_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/YIC.0000000000000052","volume":"30","author":"E Daurignac","year":"2015","unstructured":"Daurignac, E., Leonard, K. E. & Dubovsky, S. L. Increased lean body mass as an early indicator of olanzapine-induced weight gain in healthy men. Int. Clin. Psychopharmacol. 30, 23\u201328 (2015).","journal-title":"Int. Clin. Psychopharmacol."},{"key":"36930_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/JCP.0b013e31819302c3","volume":"29","author":"A Gunes","year":"2009","unstructured":"Gunes, A., Melkersson, K. I., Scordo, M. G. & Dahl, M. L. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J. Clin. Psychopharmacol. 29, 65\u201368 (2009).","journal-title":"J. Clin. Psychopharmacol."},{"key":"36930_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/hup.1114","volume":"25","author":"KI Melkersson","year":"2010","unstructured":"Melkersson, K. I., Gunes, A. & Dahl, M. L. Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patients. Hum. Psychopharmacol. 25, 347\u2013352 (2010).","journal-title":"Hum. Psychopharmacol."},{"key":"36930_CR24","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1176\/appi.ajp.159.6.1058","volume":"159","author":"M Poyurovsky","year":"2002","unstructured":"Poyurovsky, M. et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am. J. Psychiatry 159, 1058\u20131060 (2002).","journal-title":"Am. J. Psychiatry"},{"key":"36930_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3109\/13651501.2014.957705","volume":"18","author":"X Ma","year":"2014","unstructured":"Ma, X. et al. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. International journal of psychiatry in clinical practice 18, 229\u2013242 (2014).","journal-title":"International journal of psychiatry in clinical practice"},{"key":"36930_CR26","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1503\/jpn.170092","volume":"42","author":"C Kowalchuk","year":"2017","unstructured":"Kowalchuk, C. et al. In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. Journal of psychiatry & neuroscience: JPN 42, 424\u2013431 (2017).","journal-title":"Journal of psychiatry & neuroscience: JPN"},{"key":"36930_CR27","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2147\/NDT.S113099","volume":"13","author":"M Dayabandara","year":"2017","unstructured":"Dayabandara, M. et al. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr. Dis. Treat. 13, 2231\u20132241 (2017).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"36930_CR28","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/jamapsychiatry.2013.203","volume":"70","author":"L Palaniyappan","year":"2013","unstructured":"Palaniyappan, L. et al. Cortical folding defects as markers of poor treatment response in first-episode psychosis. JAMA psychiatry 70, 1031\u20131040 (2013).","journal-title":"JAMA psychiatry"},{"key":"36930_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.psyneuen.2018.05.021","volume":"95","author":"A Calevro","year":"2018","unstructured":"Calevro, A. et al. Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue. Psychoneuroendocrinology 95, 28\u201333 (2018).","journal-title":"Psychoneuroendocrinology"},{"key":"36930_CR30","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1210\/en.2015-1322","volume":"156","author":"G Schoiswohl","year":"2015","unstructured":"Schoiswohl, G. et al. Impact of Reduced ATGL-Mediated Adipocyte Lipolysis on Obesity-Associated Insulin Resistance and Inflammation in Male Mice. Endocrinology 156, 3610\u20133624 (2015).","journal-title":"Endocrinology"},{"key":"36930_CR31","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/414799a","volume":"414","author":"AR Saltiel","year":"2001","unstructured":"Saltiel, A. R. & Kahn, C. R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799\u2013806 (2001).","journal-title":"Nature"},{"key":"36930_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrm3351","volume":"13","author":"D Leto","year":"2012","unstructured":"Leto, D. & Saltiel, A. R. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat. Rev. Mol. Cell. Biol. 13, 383\u2013396 (2012).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"36930_CR33","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1038\/emboj.2011.277","volume":"30","author":"X Yu","year":"2011","unstructured":"Yu, X. et al. Egr-1 decreases adipocyte insulin sensitivity by tilting PI3K\/Akt and MAPK signal balance in mice. EMBO J. 30, 3754\u20133765 (2011).","journal-title":"EMBO J."},{"key":"36930_CR34","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fpsyt.2017.00238","volume":"8","author":"LJ De Picker","year":"2017","unstructured":"De Picker, L. J., Morrens, M., Chance, S. A. & Boche, D. Microglia and brain plasticity in acute psychosis and schizophrenia illness course: a meta-review. Frontiers in psychiatry 8, 238 (2017).","journal-title":"Frontiers in psychiatry"},{"key":"36930_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1017\/S1461145711001775","volume":"16","author":"KS MacDowell","year":"2013","unstructured":"MacDowell, K. S. et al. Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation. Int. J. Neuropsychopharmacol. 16, 121\u2013135 (2013).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"36930_CR36","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/bph.13364","volume":"173","author":"LE Laskaris","year":"2016","unstructured":"Laskaris, L. E. et al. Microglial activation and progressive brain changes in schizophrenia. British journal of pharmacology 173, 666\u2013680 (2016).","journal-title":"British journal of pharmacology"},{"key":"36930_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0688-2","volume":"13","author":"E Limoa","year":"2016","unstructured":"Limoa, E. et al. Electroconvulsive shock attenuated microgliosis and astrogliosis in the hippocampus and ameliorated schizophrenia-like behavior of Gunn rat. Journal of neuroinflammation 13, 230 (2016).","journal-title":"Journal of neuroinflammation"},{"key":"36930_CR38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/glia.22610","volume":"62","author":"E Valera","year":"2014","unstructured":"Valera, E., Ubhi, K., Mante, M., Rockenstein, E. & Masliah, E. Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy. Glia 62, 317\u2013337 (2014).","journal-title":"Glia"},{"key":"36930_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/1753425915613425","volume":"22","author":"C Faour-Nmarne","year":"2016","unstructured":"Faour-Nmarne, C. & Azab, A. N. Effects of olanzapine on LPS-induced inflammation in rat primary glia cells. Innate immunity 22, 40\u201350 (2016).","journal-title":"Innate immunity"},{"key":"36930_CR40","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev.immunol.18.1.621","volume":"18","author":"M Karin","year":"2000","unstructured":"Karin, M. & Ben-Neriah, Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18, 621\u2013663 (2000).","journal-title":"Annu. Rev. Immunol."},{"key":"36930_CR41","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.4088\/JCP.v66n0818c","volume":"66","author":"L Citrome","year":"2005","unstructured":"Citrome, L. & Volavka, J. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. J. Clin. Psychiatry 66, 1073\u20131074 (2005).","journal-title":"J. Clin. Psychiatry"},{"key":"36930_CR42","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2016.16040442","volume":"174","author":"AP Rajkumar","year":"2017","unstructured":"Rajkumar, A. P. et al. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a danish population-based cohort study. Am. J. Psychiatry 174, 686\u2013694 (2017).","journal-title":"Am. J. Psychiatry"},{"key":"36930_CR43","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.2337\/db10-0449","volume":"59","author":"PJ Martins","year":"2010","unstructured":"Martins, P. J., Haas, M. & Obici, S. Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 59, 2418\u20132425 (2010).","journal-title":"Diabetes"},{"key":"36930_CR44","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/sj.npp.1301142","volume":"32","author":"HS Vestri","year":"2007","unstructured":"Vestri, H. S., Maianu, L., Moellering, D. R. & Garvey, W. T. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 32, 765\u2013772 (2007).","journal-title":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology"},{"key":"36930_CR45","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/oby.2010.6","volume":"18","author":"RJ Fountaine","year":"2010","unstructured":"Fountaine, R. J. et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity 18, 1646\u20131651 (2010).","journal-title":"Obesity"},{"key":"36930_CR46","doi-asserted-by":"publisher","first-page":"181643","DOI":"10.1155\/2015\/181643","volume":"2015","author":"KN Keane","year":"2015","unstructured":"Keane, K. N., Cruzat, V. F., Carlessi, R., De Bittencourt, P. I. H. & Newsholme, P. Molecular events linking oxidative stress and inflammation to insulin resistance and \u03b2-cell dysfunction. Oxid. Med. Cell. Longev. 2015, 181643 (2015).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"36930_CR47","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.trsl.2015.08.011","volume":"167","author":"H Khodabandehloo","year":"2016","unstructured":"Khodabandehloo, H., Gorgani-Firuzjaee, S., Panahi, G. & Meshkani, R. Molecular and cellular mechanisms linking inflammation to insulin resistance and \u03b2-cell dysfunction. Transl. Res. 167, 228\u2013256 (2016).","journal-title":"Transl. Res."},{"key":"36930_CR48","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.bbrc.2014.07.005","volume":"450","author":"AK Sarvari","year":"2014","unstructured":"Sarvari, A. K., Vereb, Z., Uray, I. P., Fesus, L. & Balajthy, Z. Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro. Biochemical and biophysical research communications 450, 1383\u20131389 (2014).","journal-title":"Biochemical and biophysical research communications"},{"key":"36930_CR49","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.euroneuro.2015.08.004","volume":"25","author":"MC Cotel","year":"2015","unstructured":"Cotel, M. C. et al. Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses. Eur. Neuropsychopharmacol. 25, 2098\u20132107 (2015).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"36930_CR50","doi-asserted-by":"publisher","first-page":"e107116","DOI":"10.1371\/journal.pone.0107116","volume":"9","author":"C Wu","year":"2014","unstructured":"Wu, C. et al. An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine. PloS one 9, e107116 (2014).","journal-title":"PloS one"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36930-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36930-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36930-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T05:45:25Z","timestamp":1671255925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36930-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["36930"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-36930-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,7]]},"assertion":[{"value":"2 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1582"}}